Explore 3 Stock Ideas & Industry Insights Download Free Report

CStone Pharmaceuticals

Company price
0.75 USD 0.00(0%)
Last update at 2026-11-17T21:00:00Z
VOLUME
2000
Market Cap
1452.24M

Momentum Score

…

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor, has been approved by the China NMPA for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. It has strategic partnerships with Pfizer, Sanofi, Hengrui, 3SBio Inc., Allist, Ewopharma, Pharmalink, SteinCares, and Gentili. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.75
Low
0.91
High
52 Week Price Range
0.59
Low
1.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

CStone Pharmaceuticals is a China-based biopharmaceutical company focused on developing and commercializing oncology and immuno-oncology therapies, with multiple clinical-stage programs. Its long-term growth may benefit from progression of clinical programs, potential regulatory approvals, broader demand for cancer treatments in China and collaborations that could support development and market access.

Principal risks include clinical and regulatory setbacks, significant funding and execution requirements, intense competition from domestic and multinational oncology firms, and limited liquidity and disclosure constraints associated with a Pink-sheet listing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.75
Dividend Yield
-
Revenue TTM
425.23M
Revenue Per Share
0.28
Gross Profit TTM
238.24M
Debt / Equity
0.57
ROE
-52.14%
Net Debt
-405.39M
ROCE
-49.67%
Diluted EPS TTM
-0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -413.00M -91.21M -367.23M -902.68M -1920.10M
Net income -425.73M -91.21M -367.23M -902.68M -1920.10M
Selling general administrative - 33.16M 48.72M 63.17M 109.20M
Selling and marketing expenses - 133.78M 199.35M 327.30M 363.79M
Gross profit 44.79M 240.15M 304.30M 278.38M 136.89M
Reconciled depreciation - 49.80M 58.19M 44.54M 22.66M
Ebit -421.46M -76.04M -355.42M -832.27M -1852.75M
Ebitda -378.61M -26.23M -297.23M -787.73M -1830.09M
Depreciation and amortization 42.85M 49.80M 58.19M 44.54M 22.66M
Operating income -421.46M -91.69M -579.85M -832.27M -1852.75M
Other operating expenses 684.08M 498.90M 1043.69M 1384.87M 2037.19M
Interest expense 12.93M 15.17M 11.82M 8.48M 2.24M
Interest income - 12.67M 24.89M 9.67M 9.80M
Net interest income - -2.50M 13.07M 1.20M 7.56M
Income tax expense 12.73M - 58.02M - -
Total revenue 262.63M 407.20M 463.84M 481.36M 243.72M
Total operating expenses 466.24M 331.85M 884.14M 1181.89M 1930.36M
Cost of revenue 217.84M 167.05M 159.55M 202.99M 106.83M
Total other income expense net 8.46M 0.48M 212.61M -70.41M -67.35M
Net income from continuing ops - -91.21M -367.23M -902.68M -1920.10M
Net income applicable to common shares - - - - -1920.10M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1359.05M 1393.47M 1662.00M 1638.43M 2271.45M
Intangible assets - 161.37M 173.04M 159.70M 70.54M
Other current assets 43.81M - 21.85M - -
Total liab 667.49M 1029.60M 1205.17M 1189.10M 1064.44M
Total stockholder equity 617.08M 363.87M 456.83M 449.33M 1207.01M
Other current liab 231.17M 248.99M 446.99M 611.15M 855.98M
Common stock 1.00M 0.86M 0.86M 0.80M 0.80M
Capital stock - 0.86M 0.86M 0.80M 0.80M
Retained earnings - -9110.93M -9019.73M -8652.49M -7749.81M
Other liab - - - - 1.25M
Other assets 0.00M - - - 57.28M
Cash 754.08M 387.94M 996.67M 558.68M 742.72M
Total current liabilities 510.48M 682.01M 850.34M 946.48M 932.95M
Current deferred revenue 10.39M - - 585.95M -
Net debt -405.39M -31.96M -633.22M -272.39M -568.53M
Short term debt 191.68M 93.22M 139.31M 44.92M 43.95M
Short long term debt - 60.80M 105.99M 8.57M 30.70M
Short long term debt total 348.69M 355.97M 363.45M 286.29M 174.20M
Other stockholder equity 616.08M 9003.95M 8992.45M 9101.02M 1206.21M
Property plant equipment - - - - 182.80M
Total current assets 1113.75M 1089.91M 1329.79M 1246.92M 1957.64M
Net tangible assets - - - - 1136.47M
Short term investments 165.08M 285.00M 51.85M 483.41M 983.62M
Net receivables 33.83M 130.88M 172.44M 77.13M 117.60M
Long term debt - 257.40M 213.00M 218.99M 115.81M
Inventory 116.95M 286.10M 108.83M 22.19M 61.36M
Accounts payable 77.24M 338.03M 246.38M 290.41M 33.02M
Accumulated other comprehensive income - 469.99M 483.25M - -
Non currrent assets other 0.00M 287.62M 2.26M 505.17M 1035.77M
Non current assets total 245.30M 303.56M 332.21M 391.51M 313.81M
Capital lease obligations - 37.77M 44.46M 58.74M 27.69M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 123.46M -247.68M 619.61M 365.12M -687.48M
Change to liabilities - - - 0.00M 154.99M
Total cashflows from investing activities 133.99M -247.68M 619.61M - -826.55M
Net borrowings 24.20M -0.79M 91.43M - 77.72M
Total cash from financing activities 577.78M -12.90M 388.36M 28.47M 92.30M
Change to operating activities - - - - 88.49M
Net income -423.94M -91.21M -367.23M -902.68M -1920.10M
Change in cash 365.76M -608.73M 437.99M -184.04M -2281.82M
Begin period cash flow 387.94M 996.67M 558.68M 742.72M 3024.55M
End period cash flow 753.70M 387.94M 996.67M 558.68M 742.72M
Total cash from operating activities -327.75M -343.18M -588.84M -612.47M -1484.02M
Issuance of capital stock 672.46M 0.07M 341.82M 2.53M 16.83M
Depreciation 43.98M 49.80M 58.19M 44.54M 22.66M
Other cashflows from investing activities 10.53M 6.46M 171.93M - 10.06M
Change to inventory 81.99M -174.90M -95.46M 30.42M -61.36M
Change to account receivables 50.12M 48.51M -95.31M - -117.60M
Sale purchase of stock - - - - 0.00M
Other cashflows from financing activities -118.89M -12.18M -44.90M 57.94M 82.18M
Change to netincome - - - - 348.89M
Capital expenditures 0.00M 0.00M 65.05M 101.82M 149.14M
Change in working capital -75.76M -302.80M -139.67M 72.65M 64.52M
Stock based compensation 23.97M -2.81M 36.99M 142.06M 222.67M
Other non cash items 104.00M 3.83M -177.13M 30.96M 126.22M
Free cash flow -327.75M -343.18M -653.89M -714.29M -1633.16M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CSPHF
CStone Pharmaceuticals
-
-%
0.75 - - 3.42 7.54 16.33 -0.28
NVO
Novo Nordisk A/S
-1.25
3.07%
39.45 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-
-%
536.45 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-9.75
1.02%
948.01 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

CStone Pharmaceuticals

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor, has been approved by the China NMPA for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. It has strategic partnerships with Pfizer, Sanofi, Hengrui, 3SBio Inc., Allist, Ewopharma, Pharmalink, SteinCares, and Gentili. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.

C1 Building, Suzhou, China, 215123

86 512 8718 6550

102

Name Title Year Born
Dr. Ningjun Jiang M.D., Ph.D. Sr. Advisor 1961
Dr. Jianxin Yang M.D., Ph.D. CEO, Sr. VP & Chief Medical Officer 1964
Mr. Jun Cheng VP of Fin. 1980
Dr. Ngai Chiu Tse M.D., Ph.D. Sr. VP & Chief Scientific Officer 1967
Mr. Ning He Head of Legal Affairs & Joint Company Sec. NA
Mr. Michael J. Choi M.B.A. Chief Commercial Officer & Chief Strategy Officer 1975
Dr. - Zhou M.D. GM of Greater China & Head of Commercial 1981
Ms. Yin Kwan Ho Joint Company Sec. 1977
Dr. Jianxin Yang M.D., Ph.D. CEO, President of R&D and Executive Director 1964
Ms. Weicong Ni CFO & Joint Company Secretary 1991

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…